Core Viewpoint - Calidi Biotherapeutics and City of Hope are advancing a phase 1 clinical trial for CLD-101, a novel virotherapy targeting recurrent high-grade glioma, with initial results showing safety and tolerability in participants [1][2][3] Group 1: Clinical Trial Details - The phase 1 trial, conducted by City of Hope, is evaluating the safety and feasibility of administering up to four weekly intracerebral doses of CLD-101 [2] - So far, 14 participants have been treated, and all treatments have been well tolerated, with enrollment continuing for the highest treatment schedule [2][3] Group 2: Key Personnel and Funding - Dr. Jana Portnow, co-director of City of Hope's Brain Tumor Program, is optimistic about the results, particularly from cohort 4 of the trial [3] - The study has received a $12 million award from the California Institute for Regenerative Medicine to support its development [4] Group 3: Company Background - Calidi Biotherapeutics is a clinical-stage immuno-oncology company focused on using stem cell technology to deliver oncolytic virus payloads to cancer sites [5][7] - The company has licensed its technology from the University of Chicago, with City of Hope and the University of Alabama also involved [5] Group 4: City of Hope Overview - City of Hope is one of the largest cancer research and treatment organizations in the U.S., recognized for its comprehensive cancer care and research [8][9]
Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma